The application of P2X7 receptors antagonist AZ11645373 (50 nmol/L) led to reduction in [Ca2+]i in CKD patients from 120 ± 6 to 112 ± 8 nmol/L (P < 0.001, n = 16). Here, P2RX7 is linked to chronic kidney disease.